Published in Nature on July 07, 2016
Aptamers: A New Technological Platform in Cancer Immunotherapy. Pharmaceuticals (Basel) (2016) 0.79
SHP2 phosphatase as a novel therapeutic target for melanoma treatment. Oncotarget (2016) 0.78
Targeting endogenous proteins for degradation through the affinity-directed protein missile system. Open Biol (2017) 0.76
Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy. Genome Med (2017) 0.75
Cancer: Allosteric phosphatase inhibitor puts brake on cancer cells. Nat Rev Drug Discov (2016) 0.75
Critical Role for GAB2 in Neuroblastoma Pathogenesis through the Promotion of SHP2/MYCN Cooperation. Cell Rep (2017) 0.75
Modulation of VEGF receptor 2 signaling by protein phosphatases. Pharmacol Res (2016) 0.75
Decline in arylsulfatase B leads to increased invasiveness of melanoma cells. Oncotarget (2016) 0.75
Shp2 Inhibits Proliferation of Esophageal Squamous Cell Cancer via Dephosphorylation of Stat3. Int J Mol Sci (2017) 0.75
Biophysical assay for tethered signaling reactions reveals tether-controlled activity for the phosphatase SHP-1. Sci Adv (2017) 0.75
Dual Shp2 and Pten Deficiencies Promote Non-alcoholic Steatohepatitis and Genesis of Liver Tumor-Initiating Cells. Cell Rep (2016) 0.75
CD99-derived agonist ligands inhibit fibronectin-induced activation of β1 integrin through PKA/SHP2/ERK/PTPN12/FAK signaling pathway. Mol Cell Biol (2017) 0.75
T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab. PLoS One (2017) 0.75
SHP2 negatively regulates HLA-ABC and PD-L1 expression via STAT1 phosphorylation in prostate cancer cells. Oncotarget (2017) 0.75
A small-molecule allosteric inhibitor of Mycobacterium tuberculosis tryptophan synthase. Nat Chem Biol (2017) 0.75
SHP2 regulates proliferation and tumorigenicity of glioma stem cells. J Neurooncol (2017) 0.75
Features and development of Coot. Acta Crystallogr D Biol Crystallogr (2010) 89.46
XDS. Acta Crystallogr D Biol Crystallogr (2010) 67.46
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Protein-tyrosine phosphatases and cancer. Nat Rev Cancer (2006) 3.65
Crystal structure of the tyrosine phosphatase SHP-2. Cell (1998) 3.48
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol (2013) 2.50
Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. ChemMedChem (2007) 2.36
PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood (2006) 2.28
Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta (2009) 2.04
The role of Shp2 (PTPN11) in cancer. Curr Opin Genet Dev (2007) 1.97
ATARiS: computational quantification of gene suppression phenotypes from multisample RNAi screens. Genome Res (2012) 1.86
Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. Proc Natl Acad Sci U S A (2014) 1.71
Potent stimulation of SH-PTP2 phosphatase activity by simultaneous occupancy of both SH2 domains. J Biol Chem (1995) 1.66
The tyrosine phosphatase Shp2 in development and cancer. Adv Cancer Res (2010) 1.58
Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking. Proc Natl Acad Sci U S A (2008) 1.54
Voltage-gated sodium channels as therapeutic targets. Drug Discov Today (2000) 1.43
Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction. Nat Chem Biol (2014) 1.35
Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation. Cancer Sci (2009) 1.32
Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2. Biochem Biophys Res Commun (2003) 1.24
Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy. J Am Chem Soc (2003) 1.11
Therapeutic potential of targeting the oncogenic SHP2 phosphatase. J Med Chem (2014) 1.04
Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma. Oncotarget (2015) 0.95
Isoxazole carboxylic acids as protein tyrosine phosphatase 1B (PTP1B) inhibitors. Bioorg Med Chem Lett (2004) 0.92
Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097. Mol Cancer Ther (2015) 0.86
PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs. Cell Rep (2015) 0.85
Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo. ChemMedChem (2015) 0.84
Exploring the Existing Drug Space for Novel pTyr Mimetic and SHP2 Inhibitors. ACS Med Chem Lett (2015) 0.84
Shp2 protein tyrosine phosphatase inhibitor activity of estramustine phosphate and its triterpenoid analogs. Bioorg Med Chem Lett (2010) 0.83
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
A draft sequence of the rice genome (Oryza sativa L. ssp. indica). Science (2002) 42.78
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Towards a proteome-scale map of the human protein-protein interaction network. Nature (2005) 24.76
Landscape of transcription in human cells. Nature (2012) 20.18
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med (2004) 13.57
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell (2011) 11.44
Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature (2002) 10.96
High-quality binary protein interaction map of the yeast interactome network. Science (2008) 10.65
Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 9.41
An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res (2004) 8.86
Extensive promoter-centered chromatin interactions provide a topological basis for transcription regulation. Cell (2012) 8.41
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med (2006) 6.96
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93
dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics (2004) 6.78
Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science (2003) 6.68
MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 6.58
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med (2005) 6.04
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95
The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol (2004) 5.43
An experimentally derived confidence score for binary protein-protein interactions. Nat Methods (2008) 5.27
Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell (2012) 5.16
Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell (2004) 4.98
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature (2013) 4.90
Effects of cigarette smoke on the human airway epithelial cell transcriptome. Proc Natl Acad Sci U S A (2004) 4.89
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71
Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet (2007) 4.69
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med (2006) 4.63
Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat Med (2007) 4.63
hORFeome v3.1: a resource of human open reading frames representing over 10,000 human genes. Genomics (2007) 4.62
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood (2008) 4.61
Origin and function of myofibroblasts in kidney fibrosis. Nat Med (2013) 4.55
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Electrostatic basis for enzyme catalysis. Chem Rev (2006) 4.35
A gene expression network model of type 2 diabetes links cell cycle regulation in islets with diabetes susceptibility. Genome Res (2008) 4.33
Literature-curated protein interaction datasets. Nat Methods (2009) 4.21
Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest (2008) 4.13
TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell (2003) 4.13
Opposing LSD1 complexes function in developmental gene activation and repression programmes. Nature (2007) 4.12
Automatic clustering of orthologs and inparalogs shared by multiple proteomes. Bioinformatics (2006) 3.98
Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis. Kidney Int (2013) 3.97
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet (2004) 3.96
Edgetic perturbation models of human inherited disorders. Mol Syst Biol (2009) 3.96
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci U S A (2006) 3.83
A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR. Cancer Cell (2002) 3.73
Lineage dependency and lineage-survival oncogenes in human cancer. Nat Rev Cancer (2006) 3.72
Anatase TiO2 single crystals with a large percentage of reactive facets. Nature (2008) 3.66
Transgenic mice: fat-1 mice convert n-6 to n-3 fatty acids. Nature (2004) 3.65
Genome-scale analysis of in vivo spatiotemporal promoter activity in Caenorhabditis elegans. Nat Biotechnol (2007) 3.65
Sexual cycle of Cryptococcus neoformans var. grubii and virulence of congenic a and alpha isolates. Infect Immun (2003) 3.61
A PCR-based strategy to generate integrative targeting alleles with large regions of homology. Microbiology (2002) 3.58
Association between changes in air pollution levels during the Beijing Olympics and biomarkers of inflammation and thrombosis in healthy young adults. JAMA (2012) 3.52
Epstein-Barr virus and virus human protein interaction maps. Proc Natl Acad Sci U S A (2007) 3.50
High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell (2004) 3.46
Metabolic syndrome in childhood predicts adult metabolic syndrome and type 2 diabetes mellitus 25 to 30 years later. J Pediatr (2007) 3.45
The eukaryotic translation initiation factors eIF1 and eIF1A induce an open conformation of the 40S ribosome. Mol Cell (2007) 3.44
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature (2010) 3.39
Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. PLoS Comput Biol (2006) 3.39
Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation (2004) 3.38
Genome coverage and sequence fidelity of phi29 polymerase-based multiple strand displacement whole genome amplification. Nucleic Acids Res (2004) 3.37
Akt-regulated pathways in prostate cancer. Oncogene (2005) 3.35
Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol (2006) 3.34
Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci U S A (2003) 3.34
Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A (2008) 3.30
A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell (2003) 3.29
Hypothalamic programming of systemic ageing involving IKK-β, NF-κB and GnRH. Nature (2013) 3.22
Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science (2003) 3.21
PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res (2009) 3.21
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res (2004) 3.20
Histone H2A monoubiquitination represses transcription by inhibiting RNA polymerase II transcriptional elongation. Mol Cell (2008) 3.18
Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res (2009) 3.17
Single-vector inducible lentiviral RNAi system for oncology target validation. Cell Cycle (2009) 3.14
Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology (2004) 3.14
A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release. Endocrinology (2008) 3.04
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A (2012) 3.03
Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell (2008) 3.01
Modeling electrostatic effects in proteins. Biochim Biophys Acta (2006) 2.91
Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med (2010) 2.86
Allele-specific amplification in cancer revealed by SNP array analysis. PLoS Comput Biol (2005) 2.84
Poly[bis[aquaneodymium(III)]-mu2-oxalato-di-mu4-succinato]. Acta Crystallogr C (2007) 2.84
The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J (2003) 2.81